Evolution of the Management of Resectable Pancreatic Cancer. J Oncol Pract 2016 Sep;12(9):772-8
Date
09/14/2016Pubmed ID
27621326DOI
10.1200/JOP.2016.015818Scopus ID
2-s2.0-84987615728 (requires institutional sign-in at Scopus site) 26 CitationsAbstract
In pancreatic cancer, as with many other solid tumors, a commonly held surgical adage-a chance to cut is a chance to cure-has been promulgated throughout the years. Following such reasoning, surgical extirpation of a localized tumor would prevent tumor dissemination and metastatic tumor progression. However, decades of surgical experience have demonstrated that surgical resection alone provides a limited median survival benefit. Despite the optimization of surgical technique and perioperative management over the past three decades, little progress has been made to improve the limited survival of patients with localized pancreatic cancer who receive surgery. In this article, we discuss the rationale for a novel management strategy for patients with resectable pancreatic cancer, which may improve patient selection and the delivery of multimodality therapy.
Author List
Tsai S, Erickson BA, Dua K, Ritch PS, Tolat P, Evans DBAuthors
Kulwinder S. Dua MD Professor in the Medicine department at Medical College of WisconsinBeth A. Erickson MD Professor in the Radiation Oncology department at Medical College of Wisconsin
Douglas B. Evans MD Professor in the Surgery department at Medical College of Wisconsin
Parag P. Tolat MD Chief, Professor in the Radiology department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
HumansNeoadjuvant Therapy
Neoplasm Staging
Pancreatic Neoplasms
Treatment Outcome
